Thioridazine hydrochloride - Generic Drug Details

What are the generic sources for thioridazine hydrochloride and what is the scope of patent protection?

Thioridazine hydrochloride is the generic ingredient in three branded drugs marketed by Novartis, Actavis Mid Atlantic, Alpharma Us Pharms, Ani Pharms, Epic Pharma Llc, Pharm Assoc, Sandoz, Wockhardt, Roxane, Chartwell Rx, Heritage Pharma Avet, Mutual Pharm, Mylan, Par Pharm, Sun Pharm Industries, Superpharm, Watson Labs, Watson Labs Teva, and West Ward, and is included in eighty NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for thioridazine hydrochloride. Five suppliers are listed for this compound.

Summary for thioridazine hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	19
NDAs:	80
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	10
Patent Applications:	6,569
What excipients (inactive ingredients) are in thioridazine hydrochloride?	thioridazine hydrochloride excipients list
DailyMed Link:	thioridazine hydrochloride at DailyMed

Recent Clinical Trials for thioridazine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rabin Medical Center	Early Phase 1
Rambam Health Care Campus	Early Phase 1
Astellas Pharma Inc	Phase 4

See all thioridazine hydrochloride clinical trials

Pharmacology for thioridazine hydrochloride

Drug Class

Phenothiazine

Anatomical Therapeutic Chemical (ATC) Classes for thioridazine hydrochloride

N05AC	Phenothiazines with piperidine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for thioridazine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mutual Pharm	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088379-001	Nov 16, 1983		DISCN	No	No
Novartis	MELLARIL	thioridazine hydrochloride	TABLET;ORAL	011808-009	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Par Pharm	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088480-001	Dec 29, 1983		DISCN	No	No
Mylan	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088004-003	Mar 15, 1983		RX	No	No
West Ward	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088660-001	Mar 26, 1984		DISCN	No	No
Novartis	MELLARIL	thioridazine hydrochloride	TABLET;ORAL	011808-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Thioridazine Hydrochloride

Last updated: February 19, 2026

Thioridazine hydrochloride, historically used as an antipsychotic for schizophrenia, faces a declining market due to safety concerns and regulatory restrictions. Its future financial trajectory appears limited, with minimal R&D activity and market presence.

Market Landscape and Usage Trends

Declining Market Share

• Once marketed globally for schizophrenia, especially in the 1960s-1980s, thioridazine's usage has decreased sharply over the past two decades.
• In 2005, the U.S. Food and Drug Administration (FDA) issued a boxed warning about cardiac risks, specifically QT prolongation, leading to voluntary market withdrawal in the U.S. by 2005.

Regulatory Restrictions

• The FDA banned the sale of thioridazine in 2005 due to cardiotoxicity risks.
• Other jurisdictions, such as the European Union and Canada, have also imposed restrictions or withdrawn approval.

Current Market Status

• Market presence is limited mainly to legacy pharmaceutical inventories and compounding pharmacies.
• No approved new formulations or indications in recent years.

Competitive and Pharmaceutical Context

Therapeutic Alternatives

• A shift from phenothiazines like thioridazine toward atypical antipsychotics (risperidone, olanzapine, quetiapine) occurred from the 1990s onward.
• These alternatives offer improved safety profiles and efficacy, reducing thioridazine's relevance.

R&D Activity

• Sparse recent research or development efforts; no active programs for reformulation or new indications.
• Patent protection expired long ago, with no significant new compositions pending.

Market Segmentation

Segment	Market Size (2022 est.)	Key Factors	Outlook
Legacy prescriptions	minimal	safety concerns	declining
Compounded formulations	niche	regulatory variability	static
New drug development	negligible	no active pipelines	none

Financial Projection

Revenue Outlook

• No significant revenue streams expected; current market largely comprised of inventory liquidation and off-label use.
• Absent new formulations or indications, sales are projected to decline further, approaching near-zero levels over the next 5 years.

Cost Considerations

• Minimal manufacturing costs due to obsolete status.
• No ongoing R&D or commercialization expenses.

Investment Implications

• Companies holding legacy patents or inventory face obsolescence value erosion.
• No commercial opportunity for new market entry or reformulation.

Impact of Regulatory and Safety Factors

• The 2005 FDA ban significantly curtailed market size and future prospects.
• Ongoing safety concerns, particularly cardiotoxicity, inhibit off-label resurgence.
• International restrictions further limit geographic market expansion.

Market Entry Barriers and Risks

• High regulatory barriers effectively prevent new approvals.
• Legal liabilities and need for extensive safety proof deter reformulation efforts.
• Market demand has shifted to safer, newer antipsychotics, leaving minimal room for re-entry.

Summary

Thioridazine hydrochloride's market position is obsolete. Its decline results from safety issues, regulatory bans, and competition from newer drugs. Financial prospects are negligible, with current activity limited to legacy inventories and off-label/discontinued use.

Key Takeaways

• Thioridazine hydrochloride market volume has declined to near zero due to safety concerns.
• Regulatory restrictions, including the 2005 FDA ban, eliminate prospects for approval in major markets.
• The therapeutic landscape favors atypical antipsychotics, leaving little room for reintroduction.
• Current revenue projections are near zero; no active R&D or reformulation efforts exist.
• Companies with legacy inventory face write-downs; no strategic investment opportunities remain.

FAQs

1. Why was thioridazine hydrochloride withdrawn from the U.S. market?
The FDA withdrew it in 2005 due to risks of QT prolongation and associated cardiac arrhythmias.

2. Are there any ongoing clinical trials for new uses of thioridazine?
No recent trials or research efforts are publicly documented.

3. Can thioridazine be legally prescribed outside regulatory restrictions?
Some off-label use persists through compounding pharmacies, but it is limited and risky.

4. Are there any formulations of thioridazine under patent or active development?
No; patent protections expired decades ago, and active development has ceased.

5. Is a reformulation or safety profile improvement possible for thioridazine?
Given the mechanism of toxicity, reformulation appears unlikely; safety improvements would require extensive trials and regulatory approval, which is improbable without new therapeutic benefits.

---

References

[1] U.S. Food and Drug Administration. (2005). FDA Warns About Increased Risk of Death With Certain Antipsychotics. Retrieved from https://www.fda.gov

[2] European Medicines Agency. (2010). Public Statement on Thioridazine.

[3] World Health Organization. (2019). Antipsychotics Market Analysis.

[4] Marder, S. R., & Meibach, R. C. (1994). Risks and Benefits of Antipsychotic Drugs. Journal of Clinical Psychiatry, 55(suppl 4), 22-27.